JP2012530504A5 - - Google Patents

Download PDF

Info

Publication number
JP2012530504A5
JP2012530504A5 JP2012516746A JP2012516746A JP2012530504A5 JP 2012530504 A5 JP2012530504 A5 JP 2012530504A5 JP 2012516746 A JP2012516746 A JP 2012516746A JP 2012516746 A JP2012516746 A JP 2012516746A JP 2012530504 A5 JP2012530504 A5 JP 2012530504A5
Authority
JP
Japan
Prior art keywords
rsv
amino acid
recombinant
domain
rsv antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012516746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530504A (ja
JP6062245B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/059008 external-priority patent/WO2010149745A1/en
Publication of JP2012530504A publication Critical patent/JP2012530504A/ja
Publication of JP2012530504A5 publication Critical patent/JP2012530504A5/ja
Application granted granted Critical
Publication of JP6062245B2 publication Critical patent/JP6062245B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012516746A 2009-06-24 2010-06-24 組換えrsv抗原 Expired - Fee Related JP6062245B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21996409P 2009-06-24 2009-06-24
US61/219,964 2009-06-24
US33456810P 2010-05-13 2010-05-13
US61/334,568 2010-05-13
PCT/EP2010/059008 WO2010149745A1 (en) 2009-06-24 2010-06-24 Recombinant rsv antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016005403A Division JP2016128457A (ja) 2009-06-24 2016-01-14 組換えrsv抗原

Publications (3)

Publication Number Publication Date
JP2012530504A JP2012530504A (ja) 2012-12-06
JP2012530504A5 true JP2012530504A5 (OSRAM) 2013-08-08
JP6062245B2 JP6062245B2 (ja) 2017-01-18

Family

ID=42670494

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012516746A Expired - Fee Related JP6062245B2 (ja) 2009-06-24 2010-06-24 組換えrsv抗原
JP2016005403A Pending JP2016128457A (ja) 2009-06-24 2016-01-14 組換えrsv抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016005403A Pending JP2016128457A (ja) 2009-06-24 2016-01-14 組換えrsv抗原

Country Status (29)

Country Link
US (1) US9492531B2 (OSRAM)
EP (1) EP2445526B1 (OSRAM)
JP (2) JP6062245B2 (OSRAM)
KR (1) KR101696002B1 (OSRAM)
CN (1) CN102481359B (OSRAM)
AU (2) AU2010264688A1 (OSRAM)
BR (1) BRPI1015917A2 (OSRAM)
CA (1) CA2766211A1 (OSRAM)
CL (1) CL2011003273A1 (OSRAM)
CO (1) CO6480978A2 (OSRAM)
CR (1) CR20120025A (OSRAM)
CY (1) CY1117673T1 (OSRAM)
DK (1) DK2445526T3 (OSRAM)
DO (1) DOP2011000389A (OSRAM)
EA (1) EA023054B1 (OSRAM)
ES (1) ES2583257T3 (OSRAM)
HR (1) HRP20160798T1 (OSRAM)
HU (1) HUE028085T2 (OSRAM)
IL (1) IL217013B (OSRAM)
MA (1) MA33449B1 (OSRAM)
MX (1) MX2012000035A (OSRAM)
PE (1) PE20121541A1 (OSRAM)
PL (1) PL2445526T3 (OSRAM)
PT (1) PT2445526T (OSRAM)
SG (1) SG176829A1 (OSRAM)
SI (1) SI2445526T1 (OSRAM)
UA (1) UA111141C2 (OSRAM)
WO (1) WO2010149745A1 (OSRAM)
ZA (1) ZA201109199B (OSRAM)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2719406T3 (es) 2007-12-24 2019-07-10 Id Biomedical Corp Quebec Antígenos recombinantes del VSR
HRP20160859T1 (hr) * 2008-12-09 2016-09-23 Novavax, Inc. Modificirani proteini rsv f i postupci njihove upotrebe
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
CN102294027A (zh) * 2011-07-26 2011-12-28 昆明理工大学 一种呼吸道合胞病毒f2蛋白亚单位疫苗及其制备方法
EP2752199A4 (en) 2011-08-29 2015-04-29 Univ Tokushima RSV MUCOSA VACCINE
US10047116B2 (en) 2011-10-03 2018-08-14 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
CN102743750B (zh) * 2012-07-09 2013-11-20 江苏省农业科学院 一种复方免疫增强剂、禽用疫苗及其制备方法
SI2879702T1 (sl) 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
US20140037680A1 (en) * 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
CN103204943B (zh) * 2013-03-20 2014-07-23 中国科学院武汉病毒研究所 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途
BR112015025392A2 (pt) * 2013-04-08 2017-10-10 Medimmune Llc composição de vacina e método de utilização
ME03442B (me) 2013-04-25 2020-01-20 Janssen Vaccines & Prevention Bv Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
EP3030260A1 (en) * 2013-08-05 2016-06-15 GlaxoSmithKline Biologicals S.A. Combination immunogenic compositions
US9388430B2 (en) * 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
EP3319634B1 (en) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3319633B1 (en) 2015-07-07 2020-11-11 Janssen Vaccines & Prevention B.V. Vaccine against rsv
SG10202001389PA (en) 2015-12-23 2020-04-29 Pfizer Rsv f protein mutants
EP3439672B1 (en) 2016-04-05 2020-11-25 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
IL262109B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V vaccine against rsv
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN107872643A (zh) * 2016-09-23 2018-04-03 伊姆西Ip控股有限责任公司 用于视频监控系统的故障恢复方法和装置
TWI683826B (zh) * 2016-11-22 2020-02-01 國立臺灣大學 重組rsv抗原
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
US12016919B2 (en) 2017-05-30 2024-06-25 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
EP4295866A3 (en) 2017-06-14 2024-03-20 Virometix AG Cyclic peptides for protection against respiratory syncytial virus
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
KR102700187B1 (ko) * 2017-09-29 2024-08-28 에스케이바이오사이언스(주) 가용성 변형 호흡기 융합세포 바이러스 (rsv) f 단백질 항원
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
BR112020020933A2 (pt) * 2018-04-17 2021-04-06 Curevac Ag Moléculas de rna de rsv inovadoras e composições para vacinação
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
US12465633B2 (en) 2018-12-20 2025-11-11 Virometix Ag Lipopeptide building blocks and synthetic virus-like particles
US12121578B2 (en) 2019-02-28 2024-10-22 Km Biologics Co., Ltd. RSV F/G chimeric vaccine
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Rsv fタンパク質生産のための細胞培養工程
CN114685627A (zh) * 2020-12-28 2022-07-01 广州更新生物医药科技有限公司 一种预防呼吸道合胞病毒的rAAV载体疫苗
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
CN115772230A (zh) * 2022-07-18 2023-03-10 青岛硕景生物科技有限公司 一种rsv重组抗原、其制备方法及应用
IL319340A (en) 2022-09-29 2025-05-01 Pfizer Immunogenic preparations containing RSV F protein truncation
TWI888970B (zh) 2022-10-27 2025-07-01 美商輝瑞大藥廠 Rna分子
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
EP4630049A1 (en) 2022-12-11 2025-10-15 Pfizer Inc. Immunogenic compositions against influenza and rsv
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
WO2024193380A1 (zh) * 2023-03-17 2024-09-26 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗
TW202515531A (zh) 2023-07-07 2025-04-16 美商輝瑞股份有限公司 兩親性tlr7/8佐劑及其用途
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
AU617739B2 (en) 1987-12-23 1991-12-05 Pharmacia & Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
JPH08505389A (ja) 1993-01-08 1996-06-11 ジ・アップジョン・カンパニー ヒトrsウイルスのfg糖蛋白質の精製および再生方法
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
ES2149340T3 (es) 1993-11-17 2000-11-01 Om Pharma Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
KR100550132B1 (ko) 1997-09-19 2006-02-08 와이어쓰 홀딩스 코포레이션 호흡 신시티아 바이러스의 부착 (지) 단백질에서 유도된펩티드
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
HUP0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
DE69935330T2 (de) 1998-06-30 2007-10-31 Om Pharma Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
AU2002223275A1 (en) 2000-11-22 2002-06-03 Biota Scientific Management Pty Ltd A method of expression and agents identified thereby
SG141239A1 (en) 2001-01-26 2008-04-28 Selexis Sa Matrix attachment regions and methods for use thereof
ATE489968T1 (de) 2001-03-09 2010-12-15 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
EP1719511B1 (en) 2001-11-16 2008-12-10 3M Innovative Properties Company N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof
EP1592302A4 (en) 2003-02-13 2007-04-25 3M Innovative Properties Co METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
EP2298898B1 (en) 2003-10-24 2012-12-26 Selexis S.A. High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences
FR2873378A1 (fr) 2004-07-23 2006-01-27 Pierre Fabre Medicament Sa Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques
GB0422439D0 (en) 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008061243A2 (en) * 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
JP2010522540A (ja) 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
US20100261155A1 (en) 2007-06-06 2010-10-14 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
ES2719406T3 (es) 2007-12-24 2019-07-10 Id Biomedical Corp Quebec Antígenos recombinantes del VSR
WO2010006447A1 (en) 2008-07-18 2010-01-21 Id Biomedical Corporation Of Quebec Chimeric respiratory syncytial virus polypeptide antigens
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine

Similar Documents

Publication Publication Date Title
JP2012530504A5 (OSRAM)
HRP20160798T1 (hr) Rekombinantni antigeni iz rsv
JP2012530761A5 (OSRAM)
AU2014288147B2 (en) Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
JP2010522540A5 (OSRAM)
JP2015512876A5 (OSRAM)
US9060975B2 (en) Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
JP2010525806A5 (OSRAM)
HRP20161353T1 (hr) Rekombinantni rsv antigeni
JP2012532601A5 (OSRAM)
JP2018537087A5 (OSRAM)
JP2002542827A5 (OSRAM)
WO2020234300A1 (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
JP2015214545A5 (OSRAM)
NZ595063A (en) Polypeptides from neisseria meningitidis
JP2011528222A5 (OSRAM)
JP2014513952A5 (OSRAM)
JP2012082206A5 (OSRAM)
JP2011004753A5 (OSRAM)
RU2017134724A (ru) Химерные полипептиды
JP2018537089A5 (OSRAM)
WO2008156729A3 (en) Vaccines against chlamydia infection
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
JP2004537308A5 (OSRAM)